| __timestamp | Galapagos NV | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9079000 | 612613000000 |
| Thursday, January 1, 2015 | 20309000 | 650773000000 |
| Friday, January 1, 2016 | 16945000 | 619061000000 |
| Sunday, January 1, 2017 | 20559000 | 628106000000 |
| Monday, January 1, 2018 | 29641000 | 717599000000 |
| Tuesday, January 1, 2019 | 88258000 | 964737000000 |
| Wednesday, January 1, 2020 | 162170000 | 875663000000 |
| Friday, January 1, 2021 | 167218000 | 886361000000 |
| Saturday, January 1, 2022 | 239528000 | 997309000000 |
| Sunday, January 1, 2023 | 94252000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Takeda Pharmaceutical Company Limited and Galapagos NV, two industry titans, showcase contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Takeda's SG&A expenses have surged by approximately 72%, peaking at over 1 trillion yen in 2023. This reflects their aggressive expansion and investment in global markets. In contrast, Galapagos NV's expenses have fluctuated, with a notable spike in 2022, reaching nearly 240 million euros, a 150% increase from 2014. This volatility highlights their adaptive approach in a competitive market. However, data for 2024 is missing for Galapagos, leaving room for speculation on their future strategy. As these companies navigate the complexities of the pharmaceutical industry, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Galapagos NV
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
Selling, General, and Administrative Costs: AstraZeneca PLC vs Galapagos NV
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV